Anti-PD-1/CD279 Recombinant (Clone Pembrolizumab)

Programmed cell death protein 1 (PD-1), also known as CD279, is a cell surface receptor belonging to the immunoglobulin superfamily that is involved in regulation and attenuation of the adaptive immune response. It is a 288-amino acid type I transmembrane protein encoded by the PDCD1 gene in humans and is composed of a 167-amino acid ectodomain consisting of an N-loop, IgV-like domain, and a stalk region, a transmembrane domain, and a cytoplasmic tail with two tyrosine-based signaling motifs. PD-1 is expressed in activated immune cells, including CD4+ T cells, CD8+ T cells, natural killer T (NKT) cells, B cells, monocytes, and dendritic cells. Binding of PD-1 to either of its ligands, PD-L1 (Cay-28378) or PD-L2 (Cay-28379), suppresses T cell proliferation and cytokine production. PD-1 deficiency induces cardiomyopathy or lupus-like glomerulonephritis in BALB/c and C57Bl/6 mice, respectively. Increased levels of intratumoral PD-1+ immune cells are associated with increased tumor size, higher nuclear grade, and poor prognosis in patients with renal cell carcinoma. Formulations containing PD-1 blocking antibodies have been used in the treatment of various cancers. Cayman's PD-1/CD279 Recombinant Monoclonal Antibody (Clone Pembrolizumab) recognizes PD-1 from human samples. Synonyms: CD279 PDCD1 Programmed Cell Death Protein 1. Preparation: This product is a recombinant monoclonal antibody expressed in HEK293 cells.. Clone Designation: Pembrolizumab. Formulation (Request formulation change): 500 µg of PD-1 antibody. Storage Buffer: Histidine buffer, pH 6.0, with 120 mM sodium chloride and 0.02% polysorbate 80. Host: Human. Isotype: IgG4kappa. Cross Reactivity: (+) PD-1. Species Reactivity: (+) Human. Storage: -80°C. Stability: > 1 year.